Combining autophagy and immune characterizations to predict prognosis and therapeutic response in lung adenocarcinoma

Abstract

The autophagy-immune-based gene signature represents a promising tool for risk stratification in patients with lung adenocarcinoma, guiding individualized targeted therapy or immunotherapy.